Metastasis-Free Survival Endpoint Spreads To Labeling With US FDA Approval Of J&J's Erleada

Apalutamide, the first drug approved to treat non-metastatic castration-resistant prostate cancer, will also be the first NDA to have clinical summary report information made public under an FDA pilot program to increase transparency.

FDA approved background, 3D rendering, blue street sign

The swift US approval of Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc.'s Erleada (apalutamide) for treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) suggests that FDA had few concerns with the pivotal trial's novel primary endpoint.

The oral androgen receptor inhibitor was approved on Feb. 14, almost two months before the new drug application's (NDA) April...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

New EU Filings

13 Aug 2025

• By Neena Brizmohun

Ensitrelvir, Shionogi's treatment for COVID-19, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

12 Aug 2025

• By Neena Brizmohun

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.

EU Biosimilar Filings, Opinions And Approvals

06 Aug 2025

• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Japan Gives Global-First Recommendations To Taisho’s Vornorexant, Santen’s Sepetaprost

05 Aug 2025

• By Lisa Takagi

Japan gives world-first approval recommendations to two domestically originated drugs, for insomnia and glaucoma/ocular hypertension.

Research Advances And Filings Prompt EMA To Revise Alzheimer’s Trial Guideline

08 Aug 2025

• By Neena Brizmohun

Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.